Senti Biosciences, Inc. (SNTI)
SNTI Stock Price Chart
Explore Senti Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze SNTI price movements and trends.
SNTI Company Profile
Discover essential business fundamentals and corporate details for Senti Biosciences, Inc. (SNTI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 May 2021
Employees
34.00
Website
https://www.sentibio.comCEO
Timothy K. Lu
Description
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells. This allows the modified cells to interpret biological cues, make precise decisions, and react appropriately within their specific cellular surroundings. Their proprietary synthetic biology platform leverages readily available, "off-the-shelf" chimeric antigen receptor natural killer (CAR-NK) cells. This innovative approach is specifically designed to tackle formidable liquid and solid tumor cancers. Among their leading therapeutic candidates is SENTI-202. This "Logic Gated OR+NOT" off-the-shelf CAR-NK cell therapy is engineered to selectively identify and destroy acute myeloid leukemia (AML) cells, critically leaving healthy bone marrow unharmed. Another key program, SENTI-301, is a multi-armed, ready-to-use CAR-NK cell therapy being developed for the treatment of hepatocellular carcinoma (HCC). Additionally, SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy, aims to precisely eliminate colorectal cancer (CRC) cells without damaging the body's healthy tissues. Established in 2016, Senti Biosciences maintains its headquarters in South San Francisco, California.
SNTI Financial Timeline
Browse a chronological timeline of Senti Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.33, while revenue estimate is $14.93k.
Earnings released on 14 May 2026
EPS came in at -$0.14 surpassing the estimated -$0.27 by +48.15%, while revenue for the quarter reached $16.00k , meeting expectations.
Earnings released on 27 Mar 2026
EPS came in at -$0.38 surpassing the estimated -$0.43 by +11.63%, while revenue for the quarter reached $22.00k , missing expectations by -97.80%.
Earnings released on 13 Nov 2025
EPS came in at -$0.69 falling short of the estimated -$0.59 by -16.95%.
Earnings released on 7 Aug 2025
EPS came in at -$0.56 surpassing the estimated -$0.90 by +37.78%.
Earnings released on 6 May 2025
EPS came in at -$1.41 falling short of the estimated -$0.58 by -143.10%.
Earnings released on 20 Mar 2025
EPS came in at -$0.67 surpassing the estimated -$3.13 by +78.59%, while revenue for the quarter reached $5.86m , beating expectations by +109.14%.
Earnings released on 14 Nov 2024
EPS came in at -$6.31 .
Earnings released on 13 Aug 2024
EPS came in at -$2.45 .
Stock split effective on 18 Jul 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 May 2024
EPS came in at -$2.60 .
Earnings released on 21 Mar 2024
EPS came in at -$4.20 falling short of the estimated -$0.23 by -1.73k%, while revenue for the quarter reached $333.00k , beating expectations by +11.00%.
Earnings released on 13 Nov 2023
EPS came in at -$2.50 surpassing the estimated -$4.80 by +47.92%, while revenue for the quarter reached $255.00k , missing expectations by -15.00%.
Earnings released on 11 Aug 2023
EPS came in at -$4.20 surpassing the estimated -$4.80 by +12.50%, while revenue for the quarter reached $937.00k , beating expectations by +87.40%.
Earnings released on 9 May 2023
EPS came in at -$4.20 surpassing the estimated -$4.80 by +12.50%, while revenue for the quarter reached $1.04m , beating expectations by +107.20%.
Earnings released on 22 Mar 2023
EPS came in at -$4.20 surpassing the estimated -$4.70 by +10.64%, while revenue for the quarter reached $59.00k , missing expectations by -87.45%.
Earnings released on 10 Nov 2022
EPS came in at -$3.80 surpassing the estimated -$5.20 by +26.92%, while revenue for the quarter reached $1.77m , beating expectations by +14.68%.
Earnings released on 15 Aug 2022
EPS came in at -$2.65 , while revenue for the quarter reached $1.11m .
Earnings released on 9 Aug 2022
EPS came in at -$2.70 , while revenue for the quarter reached $854.00k .
Earnings released on 7 Mar 2022
EPS came in at -$2.50 , while revenue for the quarter reached $543.00k .
Earnings released on 10 Nov 2021
EPS came in at -$2.61 , while revenue for the quarter reached $926.00k .
Earnings released on 6 Aug 2021
EPS came in at -$2.75 , while revenue for the quarter reached $778.00k .
SNTI Stock Performance
Access detailed SNTI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
